Teleflex Incorporated Release: ARROW Endurance Extended Dwell Peripheral Catheter System Receives FDA Market Clearance

Catheter System Designed to Provide Peripheral Vascular Access “When a PIV is Not Enough and a PICC is Too Much”

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a global provider of medical devices for critical care and surgery, announced today that its ARROW Endurance™ Extended Dwell Peripheral Catheter System received market clearance from the U.S. Food and Drug Administration (FDA).

“This is the ideal solution when patients need IV therapy for more than the few days that a traditional PIV allows but don’t require a PICC.”

The new device is a peripheral catheter system in which the catheter is cleared by the FDA to dwell up to 29 days. The extended dwell catheter enables hospitals to avoid using multiple PIVs to achieve longer dwell times while also avoiding the extra clinical risks and expenses associated with a peripherally inserted central catheter (PICC). The intravascular catheter is intended for short-term use (up to 29 days) to permit delivery of infusion therapies, pressure monitoring, high pressure injection (325 psi max.), and withdrawal of blood.

“The ARROW Endurance™ Extended Dwell Peripheral Catheter System is yet another offering from Teleflex that helps vascular access professionals provide the right line for the right patient at the right time,” said Jay White, president of Teleflex’s Vascular Access Division. “This is the ideal solution when patients need IV therapy for more than the few days that a traditional PIV allows but don’t require a PICC.”

Designed to maximize performance and ease-of-use, the extended dwell system is engineered to increase safety for clinicians and reduce needle sticks for patients. The device contains a passive needle safety that reduces the risk of accidental needle stick injuries and exposure to blood. The closed system design makes it less likely that clinicians will accidentally come in contact with bloodborne pathogens.

Teleflex expects to launch the ARROW Endurance™ Extended Dwell Peripheral Catheter System in the United States later this year.

To learn more about the Arrow® Vascular portfolio from Teleflex, please visit ArrowVascular.com.

About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Wayne, PA, Teleflex employs approximately 12,200 people and serves healthcare providers worldwide. For additional information about Teleflex please refer to www.teleflex.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, Arrow, and Arrow Endurance are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. © 2015 Teleflex Incorporated. All rights reserved. MC-001435